Literature DB >> 1689392

Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.

K J Wiegers1, K Wetz, R Dernick.   

Abstract

We obtained neutralizing monoclonal antibodies against a continuous neutralization epitope on VP2 of poliovirus type 1 strain Mahoney by using a combined in vivo-in vitro immunization procedure. The antibody-binding site was mapped to amino acid residues within the peptide segment (residues 164 through 170) of VP2 by competition with synthetic peptide and sequencing of resistant mutants. Cross-neutralization of these mutants with another neutralizing monoclonal antibody revealed a linkage of the continuous epitope and a discontinuous neutralization epitope involving both loops of the double-loop structure of VP2 at the twofold axis on the surface of the virion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689392      PMCID: PMC249245     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

2.  Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.

Authors:  M Ferguson; D M Evans; D I Magrath; P D Minor; J W Almond; G C Schild
Journal:  Virology       Date:  1985-06       Impact factor: 3.616

3.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

4.  Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.

Authors:  P D Minor; D M Evans; M Ferguson; G C Schild; G Westrop; J W Almond
Journal:  J Gen Virol       Date:  1985-05       Impact factor: 3.891

5.  Absence of glycoproteins in poliovirus particles.

Authors:  R Drzeniek; P Bilello
Journal:  J Gen Virol       Date:  1974-10       Impact factor: 3.891

6.  Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.

Authors:  P van der Marel; T G Hazendonk; M A Henneke; A L van Wezel
Journal:  Vaccine       Date:  1983-12       Impact factor: 3.641

7.  Identification of a new neutralization antigenic site on poliovirus coat protein VP2.

Authors:  E A Emini; B A Jameson; E Wimmer
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  Antigenic variation and resistance to neutralization in poliovirus type 1.

Authors:  D C Diamond; B A Jameson; J Bonin; M Kohara; S Abe; H Itoh; T Komatsu; M Arita; S Kuge; A Nomoto
Journal:  Science       Date:  1985-09-13       Impact factor: 47.728

9.  Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.

Authors:  B Sherry; A G Mosser; R J Colonno; R R Rueckert
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

10.  Binding site of neutralizing monoclonal antibodies obtained after in vivo priming with purified VP1 of poliovirus type 1 is located between amino acid residues 93 and 104 of VP1.

Authors:  K J Wiegers; R Dernick
Journal:  Virology       Date:  1987-03       Impact factor: 3.616

View more
  7 in total

1.  Combined cell culture enzyme-linked immunosorbent assay for quantification of poliovirus neutralization- relevant antibodies.

Authors:  A F Wahby
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Molecular basis of antigenic structures of poliovirus: implications for their evolution during morphogenesis.

Authors:  K Wiegers; R Dernick
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera.

Authors:  B Y Reimann; R Zell; R Kandolf
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.

Authors:  L Fiore; B Ridolfi; D Genovese; G Buttinelli; S Lucioli; A Lahm; F M Ruggeri
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Residues involved in the antigenic sites of transmissible gastroenteritis coronavirus S glycoprotein.

Authors:  F Gebauer; W P Posthumus; I Correa; C Suñé; C Smerdou; C M Sánchez; J A Lenstra; R H Meloen; L Enjuanes
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

7.  Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.

Authors:  Darja Kanduc; Candida Fasano; Giovanni Capone; Antonella Pesce Delfino; Michele Calabrò; Lorenzo Polimeno
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.